Overview

Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

Status:
Not yet recruiting

Trial end date:
2023-02-28

Target enrollment:

Participant gender:

Summary

Open-label study of an investigational product (IP), QLS-101, with 28-day every morning (QAM) dosing to both eyes (OU) in adolescents with SWS who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.

Phase:

Phase 2

Details

Lead Sponsor:

Qlaris Bio, Inc.

Treatments:

Ophthalmic Solutions